Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from Shanghai Henlius Biotech, Inc. Class H ( (HK:2696) ).
Shanghai Henlius Biotech has begun dosing the first patient in a phase 1b/2 clinical trial of HLX701, a recombinant human SIRPα-IgG4 Fc fusion protein injection, combined with cetuximab and chemotherapy for advanced colorectal cancer in mainland China. The study will compare HLX701 plus standard regimens FOLFOX or FOLFIRI against placebo, progressing through dose-escalation, dose-finding and randomized, double-blind multi-centre stages to evaluate safety, efficacy, pharmacokinetics and biomarker correlations.
HLX701, in-licensed from FBD Biologics, is designed to block CD47-mediated anti-phagocytic signalling to boost macrophage-mediated tumour cell clearance and has shown synergistic effects with multiple targeted and immune therapies in preclinical studies. With no SIRPα-Fc fusion protein targeting CD47 yet approved globally, Henlius’s progress into phase 1b/2 for colorectal cancer underscores its ambitions in next-generation immuno-oncology and, if successful, could strengthen its competitive position in a high-need solid tumour segment while expanding its innovation pipeline in key emerging markets.
The most recent analyst rating on (HK:2696) stock is a Buy with a HK$99.78 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
More about Shanghai Henlius Biotech, Inc. Class H
Shanghai Henlius Biotech, Inc. is a China-based biopharmaceutical company focused on developing, manufacturing and commercialising innovative biologic therapies, with a portfolio that includes oncology and immunology drugs. The company holds exclusive regional rights to HLX701, a SIRPα-Fc fusion protein targeting CD47, for China (excluding Taiwan), parts of Southeast Asia, and the Middle East and North Africa.
Average Trading Volume: 963,395
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$24.31B
See more data about 2696 stock on TipRanks’ Stock Analysis page.